Acorn Capital Advisors, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 19, 2025), Acorn Capital Advisors, LLC reported 22 stock positions worth $149.9 million. Its top holding was CG Oncology (CGON) at 18.5% of the portfolio, followed by Urogen Pharma (URGN, 11.2%) and Y-Mabs Therapeutics (YMAB, 9.6%). Compared with Q4 2024, it opened 1 new position, added to 7 and reduced 2. The biggest buy was Trevi Therapeutics (TRVI, shares +7%) and the biggest sale Mural Oncology (MURA, shares −1%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002054410
- Portfolio Value
- $149.9M (Q1 2025)
- SEC Filing
- 0001636587-25-000021 ↗ filed May 19, 2025
Holdings Value
Holdings 22 stocks · $149.9M
| CGON CG Oncology Inc. | 18.49% | 1,131,501 | $27.7M | No change |
| URGN Urogen Pharma Ltd. | 11.18% | 1,516,303 | $16.8M | No change |
| YMAB Y-Mabs Therapeutics Inc. | 9.56% | 3,235,387 | $14.3M | Add +13.1% |
| TRVI Trevi Therapeutics Inc. | 9.00% | 2,144,844 | $13.5M | Add +7.2% |
| CADL Candel Therapeutics Inc. | 8.11% | 2,152,252 | $12.2M | Add +11.0% |
| PBYI Puma Biotechnology Inc. | 7.78% | 3,940,052 | $11.7M | No change |
| BCAX Bicara Therapeutics Inc. | 5.59% | 643,382 | $8.4M | Add +0.0% |
| TARA Protara Therapeutic Inc. | 3.64% | 1,279,800 | $5.5M | No change |
| TERN Terns Pharmaceuticals Inc. | 3.63% | 1,971,264 | $5.4M | No change |
| OKUR Onkure Therapeutics Inc. Class A | 3.42% | 1,439,674 | $5.1M | No change |
| VSTM Verastem Inc. | 3.13% | 779,498 | $4.7M | No change |
| HELP Cybin Inc. | 3.11% | 734,394 | $4.7M | Add +0.0% |
| CRDF Cardiff Oncology Inc. | 3.02% | 1,442,308 | $4.5M | No change |
| OPTINOSE INC | 2.59% | 422,814 | $3.9M | Add +0.0% |
| WHWK Whitehawk Therapeutics Inc. | 1.35% | 1,139,363 | $2.0M | Reduce -0.7% |
| XFOR X4 Pharmaceuticals Inc. | 1.17% | 7,310,650 | $1.8M | No change |
| MURA Mural Oncology PLC | 1.07% | 1,269,715 | $1.6M | Reduce -1.3% |
| AURA Aura Biosciences Inc. | 0.97% | 590,508 | $1.5M | New |
| BCAB Bioatla Inc. | 0.94% | 4,032,046 | $1.4M | No change |
| QTTB Q32 Bio Inc. | 0.88% | 803,425 | $1.3M | No change |
| VYNE THERAPEUTICS INC | 0.83% | 785,938 | $1.2M | Add +72.0% |
| ACRV Acrivon Therapeutics Inc. | 0.55% | 405,237 | $823K | No change |
Portfolio Sells Q4 2024 → Q1 2025
Portfolio Buys Q4 2024 → Q1 2025
| TRVI Trevi Therapeutics Inc. | Add +7.2% | 9.00% | +4.56 |
| OPTINOSE INC | Add +0.0% | 2.59% | +1.07 |
| AURA Aura Biosciences Inc. | New | 0.97% | +0.97 |
| VYNE THERAPEUTICS INC | Add +72.0% | 0.83% | +0.00 |
| HELP Cybin Inc. | Add +0.0% | 3.11% | −0.38 |
| BCAX Bicara Therapeutics Inc. | Add +0.0% | 5.59% | −0.44 |
| CADL Candel Therapeutics Inc. | Add +11.0% | 8.11% | −0.95 |
| YMAB Y-Mabs Therapeutics Inc. | Add +13.1% | 9.56% | −2.50 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $366.5M | CGON, URGN, TRVI, CADL, PBYI |
| Q1 2026 | 22 | $351.8M | TERN, CGON, URGN, PBYI, TRVI |
| Q4 2025 | 21 | $295.1M | TERN, CGON, URGN, TRVI, PBYI |
| Q3 2025 | 20 | $197.0M | CGON, URGN, PBYI, TRVI, TERN |
| Q2 2025 | 21 | $152.9M | CGON, URGN, YMAB, PBYI, CADL |
| Q1 2025Amended | 22 | $149.9M | CGON, URGN, YMAB, TRVI, CADL |
| Q4 2024Amended | 21 | $185.8M | CGON, YMAB, CADL, URGN, PBYI |